These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28460576)

  • 1. Pharmacokinetic and pharmacodynamic alterations in older people with dementia.
    Reeve E; Trenaman SC; Rockwood K; Hilmer SN
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):651-668. PubMed ID: 28460576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in drug disposition in older adults: a focus on geriatric syndromes.
    Maher D; Ailabouni N; Mangoni AA; Wiese MD; Reeve E
    Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):41-52. PubMed ID: 33078628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in drug disposition in older adults.
    Reeve E; Wiese MD; Mangoni AA
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):491-508. PubMed ID: 25600059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinically relevant drug-drug interactions among elderly people with dementia.
    Sönnerstam E; Sjölander M; Lövheim H; Gustafsson M
    Eur J Clin Pharmacol; 2018 Oct; 74(10):1351-1360. PubMed ID: 29967921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and pharmacodynamic alterations in the geriatric patient.
    Delafuente JC
    Consult Pharm; 2008 Apr; 23(4):324-34. PubMed ID: 18454589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADME-tox issues for the elderly.
    Hilmer SN
    Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1321-31. PubMed ID: 18798701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.
    Velenosi TJ; Urquhart BL
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1131-43. PubMed ID: 24961255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug reactions in special populations - the elderly.
    Davies EA; O'Mahony MS
    Br J Clin Pharmacol; 2015 Oct; 80(4):796-807. PubMed ID: 25619317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations.
    Weersink RA; Burger DM; Hayward KL; Taxis K; Drenth JPH; Borgsteede SD
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):45-57. PubMed ID: 31810397
    [No Abstract]   [Full Text] [Related]  

  • 10. The current state of knowledge on age, sex, and their interactions on clinical pharmacology.
    Schwartz JB
    Clin Pharmacol Ther; 2007 Jul; 82(1):87-96. PubMed ID: 17495875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medicines and frailty in older people. Towards a new nosological entity: A pharmacological frailty?].
    Nessighaoui H; Géniaux H; Dantoine T; Laroche ML
    Therapie; 2016 Jun; 71(3):275-9. PubMed ID: 27235650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of the least frail adults with intellectual disabilities: a positive biology perspective.
    Schoufour JD; van Wijngaarden J; Mitnitski A; Rockwood K; Evenhuis HM; Echteld MA
    Res Dev Disabil; 2014 Jan; 35(1):127-36. PubMed ID: 24252590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy during pediatric extracorporeal membrane oxygenation: a review.
    Himebauch AS; Kilbaugh TJ; Zuppa AF
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1133-42. PubMed ID: 27322360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I).
    Besunder JB; Reed MD; Blumer JL
    Clin Pharmacokinet; 1988 Apr; 14(4):189-216. PubMed ID: 3292100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Horizons in the impact of frailty on pharmacokinetics: latest developments.
    Hilmer SN; Kirkpatrick CMJ
    Age Ageing; 2021 Jun; 50(4):1054-1063. PubMed ID: 33751018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of high physical activity on pharmacokinetic drug interactions.
    Lenz TL
    Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):257-66. PubMed ID: 21244343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters.
    Smit C; De Hoogd S; Brüggemann RJM; Knibbe CAJ
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):275-285. PubMed ID: 29431542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medications affecting functional status in older persons.
    Corsonello A; Onder G; Maggio M; Corica F; Lattanzio F
    Curr Pharm Des; 2014; 20(19):3256-63. PubMed ID: 24050161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review on pharmacokinetics and pharmacodynamics and the aging kidney.
    Aymanns C; Keller F; Maus S; Hartmann B; Czock D
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):314-27. PubMed ID: 20056753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a frailty index to identify potentially inappropriate prescribing and adverse drug reaction risks in older patients.
    Cullinan S; O'Mahony D; O'Sullivan D; Byrne S
    Age Ageing; 2016 Jan; 45(1):115-20. PubMed ID: 26683048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.